Drug Type Small molecule drug |
Synonyms PF 114, PF-114 mesylate |
Target |
Mechanism Bcr-Abl T315I inhibitors(BCR-ABL T315I mutation inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC29H27F3N6O |
InChIKeySLIVDYMORZGPLW-UHFFFAOYSA-N |
CAS Registry1416241-23-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Philadelphia chromosome positive chronic myelogenous leukemia | Phase 2 | RU | 01 Jul 2016 |
NCT02885766 (ASH2021) Manual | Phase 1/2 | Chronic phase chronic myeloid leukemia BCR-ABL1 T315I Mutation | 51 | PF-114 | tevdutqztg(hyqeefahhy) = grade ~ 3 psoriasis ~ like skin at 600 mg xdvdcwcvjx (seaxoypzvg ) | Positive | 05 Nov 2021 |